STML was up 15.44% earlier, but it is now up only 9.60% at present.<g>
It announced today that it will present at the Cowen and Company 36th Annual Health Care Conference on Boston, on Wednesday, Mar9, at 8:40 AM.<g>
STML is developing three clinical stage product candidates, SL-401, SL-801, and SL-701.
A trial with SL-401, directed to the interleukin-3 receptor (IL-3R; CD123), which is present on a wide range of hematologic cancers, is enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Data from the initial stage demonstrated high overall response rates, with multiple complete responses.<g>
A study with its SL-701, an immunotherapy designed to activate the immune system to attack tumors, is been adding adult patients with second-line GBM. <g>
And its SL-801, an oral small molecule reversible inhibitor of XPO1, has an open IND and is being advanced into clinical trials across multiple cancer types.<g>
The stock was up 15.44% at 11:15 AM but is up only 9.60% at present.<g>
elite.finviz.com
Bernard |
